Latest news
Korea's Alteogen inks $365 M deal for development and commercialisation of Hybrozyme™-enabled subcutaneous biologic product - BioSpectrum AsiaBioSpectrum Asia · Thu, 06 Aug 2026 12:06:10 GMTAlteogen Licenses Subcutaneous Platform to Undisclosed Global Pharma Company in Deal Worth Up to $365 Million - biopharminternational.combiopharminternational.com · Wed, 05 Aug 2026 19:10:58 GMTAlteogen Inks Licensing Pact with Global Pharma Company to Develop, Commercialize Subcutaneous Biologic - Contract PharmaContract Pharma · Wed, 05 Aug 2026 15:57:30 GMTAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product - finance.yahoo.comfinance.yahoo.com · Wed, 05 Aug 2026 12:00:00 GMT